Skip To Main Content
Sequist LV on Muck Rack

Sequist LV

As seen in: Cancer Discovery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sequist

Contact Sequist, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial | Cancer Discovery

|
By Sequist LV, Yang JC, O'Byrne K, Lim SW
| Cancer Discovery Verified
Research Articles Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylvie Vincent, Steven Zhang, Jianchang Lin, Veronica Bunn, Shu Jin, Shuanglian Li and Pasi A.
Open in Who Shared Issue with article?

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer

|
By Sequist LV, Yang JC, O'Byrne K
| Cancer Discovery Verified
Research Articles Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker, Alexandra E. Gould, Shuai Li, Scott D. Wardwell, Sara Nadworny, Yaoyu Ning, Sen Zhang, Wei-Sheng Huang, Yongbo Hu, Feng Li, Matthew T. Greenfield, Stephan G. Zech, Biplab Das, Narayana I. Narasimhan, Tim Clackson, David Dalgarno, William C. Shakespeare, Michael Fitzgerald, Johara Chouitar, Robert J. Griffin, Shengwu Liu, Kwok-kin Wong, Xiaotian Zhu and Victor M.
Open in Who Shared Issue with article?

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

|
By O'Byrne K, Sequist LV, Yang JC, Byron SA
| cancerres.aacrjournals.org
Tumor Biology and Immunology Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, Hiroaki Ochiiwa, Yayoi Fujioka, Kimihiro Ito, Akihiro Miura, Takeshi Sagara, Satoru Ito, Hirokazu Ohsawa, Sachie Otsuki, Kaoru Funabashi, Masakazu Yashiro, Kenichi Matsuo, Kazuhiko Yonekura and Hiroshi Hirai DOI: 10.1158/0008-5472.CAN-19-2568 Published November 2020 Abstract FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors.
Open in Who Shared Issue with article?
See all 3 articles